Factors Related to Significant Improvement of Estimated Glomerular Filtration Rates in Chronic Hepatitis B Patients Receiving Telbivudine Therapy
Table 2
Comparisons of the changes in the mean eGFR (CKD-EPI) of different subgroups of chronic hepatitis B patients treated with telbivudine therapy over time.
Wald chi-square
df
value
HBeAg
Positive versus negative
1.04
1
0.308
Time
31.21
7
0.000
Interaction term
14.32
7
0.046
Cirrhosis
Yes versus no
0.16
1
0.691
Time
24.57
7
0.001
Interaction term
1.34
7
0.987
Complete response at 6th month
Yes versus no
0.26
1
0.607
Time
34.30
7
0.000
Interaction term
7.81
7
0.350
Decompensation
Yes versus no
2.01
1
0.156
Time
21.66
7
0.003
Interaction term
5.37
7
0.614
HBV DNA ≥ 7 log IU/mL
Yes versus no
0.00
1
0.966
Time
32.72
7
0.000
Interaction term
6.40
7
0.494
Age ≥ 50 years
Yes versus no
11.77
1
0.001
Time
37.42
7
0.000
Interaction term
21.15
7
0.004
Genotype
B versus C
5.39
1
0.020
Time
19.14
7
0.008
Interaction term
11.57
7
0.116
Analysis by generalized estimating equations. df: degree of freedom.
